| Project/Area Number |
25640096
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
MATSUYAMA Shutoku 国立感染症研究所, ウイルス第三部四室, 室長 (90373399)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | MHV / CEACAM1a / マウス肝炎ウイルス |
|---|
| Outline of Final Research Achievements |
A murine coronavirus, mouse hepatitis virus (MHV), infects mouse cells and induces cell death. Our purpose of this study is to develop a molecular adaptor of MHV infection to induce oncolysis in target cells. This virus infects cells using a cell surface protein CEACAM1a. MHV is able to infect human cells when the expression plasmid of CEACAM1a was transfected. The 74 amino acid sequence of N-terminal domain in CEACAM1a is known to have a receptor function for MHV infection, and the binding ability of CEACAM1a to MHV is stable after denaturation with boiling. First, we had studied to find a minimum domain of viral receptor function in CEACAM1a, then the minimum domain was connected to the IgG, which named "MHV-adapter", to recognize the cell surface protein of human derived cell lines. In this moment, we unfortunately have not developed the functional MHV adapter, yet.
|
